Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Inclusion Criteria:

• Age equal or over 18 and under 90 years old.
• Confirmed COVID-19 positive diagnostic through PCR.
• Radiological image compatible with non-cardiogenic bilateral pleuropulmonary exudate.
• Patient has received anti-viral and anti-inflammatory therapy.
• Present any of the following clinical-functional criteria:

1. Respiratory distress: Tachypnea> 30 breaths / minute
2. Partial arterial oxygen pressure (PaO2) / Fraction of inspiration (FiO2) ≤ 300mmHg

• Signed informed consent, directly or delegated.

Exclusion Criteria:

• Severe liver dysfunction (Child Pugh ≥ 3 or AST> 5 times normal)
• Severe renal dysfunction with glomerular filtration <30 mL / minute or under treatmentwith hemodialysis or peritoneal dialysis.
• Poorly controlled hypertension (BPs> 160 mmHg or TAd <100 mmHg) or having a historyprevious hypertensive crisis or hypertensive encephalopathy.
• History of poorly controlled heart disease with a NYHA> 2.
• History of thrombosis in the previous 6 months.
• Signs of active bleeding.
• Open wounds, gastrointestinal perforation.
• Diagnosis of thrombophilic diseases or hemorrhagic diathesis.
• Active viral hepatitis or HIV not properly treated.
• Intolerance or allergy to bevacizumab or its components.
• Pregnancy.